London
· Delayed Price · Currency is GBP · Price in GBX Theracryf Company Description
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders.
The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma.
In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy.
The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024.
Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Huw Jones |
Contact Details
Address: Alderley Park Nether Alderley, SK10 4TG United Kingdom | |
| Phone | 44 1625 315 090 |
| Website | theracryf.com |
Stock Details
| Ticker Symbol | TCF |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | April - March |
| Reporting Currency | GBP |
| ISIN Number | GB00BSVYN304 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Huw Jones | Chief Executive Officer |
| Toni Haenninen | Chief Financial Officer |